Frontotemporal dementia (FTD) is the second most common type of primary degenerative dementia. Some patients present an overlap between Alzheimer's disease (AD) and FTD both in neuropathological and clinical aspects. This may suggest a similar overlap in physiopathology, namely an involvement of mitochondrial DNA (mtDNA) in FTD, as it has been associated to AD. To determine if mtDNA is involved in FTD, we performed a Polymerase Chain ReactionRestriction Fragment Length Polymorphism (PCR -RFLP) analysis, specific to mtDNA NADH Dehydrogenase subunit 1 (ND1) nucleotides 3337 -3340, searching for mutations previously described in Parkinson's and AD patients. We could identify one FTD patient with two mtDNA transitions: one already known (3316 G-to-A) and another unreported (3337 G-to-A). Additionally, mitochondrial respiratory chain complex I activity was reduced in leukocytes of this patient (36% of the control mean activity). To our knowledge, this is the first report of mtDNA variants in FTD patients. D 2004 Elsevier Inc. All rights reserved.
Introduction
Frontotemporal dementia (FTD) is the second most common type of primary degenerative dementia (Andreasen et al., 1999; Brun, 1993) . FTD is the generic designation of a group of disorders, which includes Frontal Lobe Dementia, Pick Disease and Motor Neuron Disease (Brun et al., 1994) , as well as inherited neurodegenerative diseases that have been linked to chromosome 17, termed FTDP-17 (Lee et al., 2001) . Although these dementias have been difficult to characterise due to their clinical variability, the most common feature is a predominant frontal lobe syndrome (Sjögren et al., 1997) , which sometimes can also be observed in more severe cases of Alzheimer's disease (AD) and in Vascular Dementia (Neary, 1990) . The early appearances of behavioural symptoms, mild memory impairment and preservation of spatial orientation are the most remarkable differences between FTD and AD (Barber et al., 1995) . Parkinsonian symptoms and motor neuron dysfunction may be observed in special forms of FTD and are useful in the differentiation between the two conditions (Foster et al., 1997) . Because it often affects people or families in midlife, FTD is also frequently confused with primary psychiatric disorders (McKhann et al., 2001; Stevens et al., 1998) .
Neuropathology in FTD is characterised by loss of neurons, neuropil vacuolation and gliosis in the superficial cortical layers of the frontal and anterior temporal lobes (Brun, 1993) , basal ganglia and substantia nigra (Rizzu et al., 1999) , and by the presence of pathological tau proteins (Vermersch et al., 1995) , which are also observed in the brain of AD patients (Foster et al., 1997; Sjögren et al., 2000; Spillantini et al., 1998) . Tau protein is a phosphoprotein associated with microtubules and responsible for its assembly and stabilization (Goedert et al., 1991) . Self-association of hyperphosphorylated and insoluble form of tau protein in straight and twisted filaments creates argyrophilic or T-positive neuropil inclusions with or without the characteristics of pick bodies or ballooned neurons, as well as argyrophilic or T-positive glial inclusions (Spillantini et al., 1998) . The biochemical analyses of tau protein abnormalities have proven to be useful in the classification of FTD (Dickson, 1997) .
By linkage analysis, FTDP-17 was localized at chromosome 17q21 -q23 (Lynch et al., 1994) and Wilhelmsen et al. (1994) mapped the disinhibition -dementia -parkinsonism -amyotrophy complex locus to 17q21 -q22. The first missense and splice site mutations in a family pedigree with FTDP-17 were found in the tau gene (Hutton et al., 1998) , and several mutations have been described ever since in this gene among the different families with cases diagnosed as FTDP-17 (Buée and Delacourte, 2001 ). However, only 10 -15% of cases of FTD exhibit mutations in the Tau gene (Wilhelmsen et al., 2001) . Raux et al. (2000) found a previously unreported heterozygous CTA-to-CCA mutation at codon 113 of the Presenilin 1 (PS1) gene, and this finding implies that the presence of PS1 mutations must be considered in FTD pedigrees with no detectable Tau gene mutation. Recently, Gydesen et al. (2002) have identified and studied a large kindred with FTD inherited as an autosomal dominant trait, which was mapped to the pericentromeric region of chromosome 3, suggesting that 
